D019172ProceduresE02.095.465.425.450.800E05.478.610.80021822240.514921Transplantation ConditioningFaculty Rankprns:fullNamefull nameprns:hasAuthorListauthor listprns:hasFacultyRankhas faculty rankprns:hasNetworkhas networkprns:hasPublicationVenuepublished inprns:informationResourceReferenceinformation resource referenceprns:isPrimaryPositionis primary positionprns:maxWeightmaximum weightprns:medlineTAjournal title abbreviationprns:meshDescriptorUIMeSH DescriptorUIprns:meshSemanticGroupNameMeSH semantic group nameprns:meshTreeNumberMeSH tree numberprns:minWeightminimum weightprns:numberOfAuthorsnumber of authorsprns:numberOfConnectionsnumber of connectionsprns:numberOfPublicationsnumber of publicationsprns:personIdPerson IDprns:personInPrimaryPositionperson in primary positionprns:positionInDepartmentposition in departmentprns:positionInDivisionposition in divisionprns:predicateNodepredicate nodeprns:publicationDatepublication dateprns:sortOrdersort orderprns:uniquenessWeightuniqueness weightprns:yearyearAcademic ArticleArticleDocumentbibo:pmidPubMed IdentifierDepartmentDivisionvivo:hrJobTitleHR job titleInformation ResourcePositionvivo:positionInOrganizationposition in organizationvivo:preferredTitlepreferred titlevivo:researchAreaOfresearch area ofvivo:subjectAreaForsubject area forrdf:predicatepredicaterdf:typetyperdfs:labellabelConceptAgentfoaf:firstNamefirst namefoaf:lastNamelast nameOrganizationPersonStem Cell TransplantationMD AndersonRICHARD ECHAMPLINRICHARD E CHAMPLIN8508CHAMPLIN, RICHARD EProfessorPARTOWKEBRIAEIPARTOW KEBRIAEI8535KEBRIAEI, PARTOWProfessorBORJE SANDERSSONBORJE S ANDERSSON8564ANDERSSON, BORJE SProfessorUDAY RPOPATUDAY R POPAT8670POPAT, UDAY RProfessorSTEFAN OCTAVIANCIUREASTEFAN OCTAVIAN CIUREA9422CIUREA, STEFAN OCTAVIANAssociate Professor74Professor14Associate Professor14.64080.00559836218research area of0.9043130.0359377616subject area for34106753Nakamura R, Saber W, Martens MJ, Ramirez A, Scott B, Oran B, Leifer E, Tamari R, Mishra A, Maziarz RT, McGuirk J, Westervelt P, Vasu S, Patnaik M, Kamble R, Forman SJ, Sekeres MA, Appelbaum F, Mendizabal A, Logan B, Horowitz M, Cutler CJournal of clinical oncology : official journal of the American Society of Clinical OncologyBiologic Assignment Trial of Reduced-Intensity Hematopoietic Cell Transplantation Based on Donor Availability in Patients 50-75 Years of Age With Advanced Myelodysplastic Syndrome. J Clin Oncol. 2021 10 20; 39(30):3328-3339.J Clin Oncol2021-06-09T00:00:002021Biologic Assignment Trial of Reduced-Intensity Hematopoietic Cell Transplantation Based on Donor Availability in Patients 50-75 Years of Age With Advanced Myelodysplastic Syndrome.34135465Oran B, Champlin RE, Wang F, Tanaka T, Saliba RM, Al-Atrash G, Garcia-Manero G, Kantarjian H, Cao K, Shpall EJ, Alousi AM, Mehta RS, Popat U, Futreal A, Takahashi KLeukemiaDonor clonal hematopoiesis increases risk of acute graft versus host disease after matched sibling transplantation. Leukemia. 2022 01; 36(1):257-262.Leukemia2021-06-16T00:00:002021Donor clonal hematopoiesis increases risk of acute graft versus host disease after matched sibling transplantation.34855460Luznik L, Pasquini MC, Logan B, Soiffer RJ, Wu J, Devine SM, Geller N, Giralt S, Heslop HE, Horowitz MM, Jones RJ, Litzow MR, Mendizabal A, Muffly L, Nemecek ER, O'Donnell L, O'Reilly RJ, Palencia R, Schetelig J, Shune L, Solomon SR, Vasu S, Ho VT, Perales MAJournal of clinical oncology : official journal of the American Society of Clinical OncologyRandomized Phase III BMT CTN Trial of Calcineurin Inhibitor-Free Chronic Graft-Versus-Host Disease Interventions in Myeloablative Hematopoietic Cell Transplantation for Hematologic Malignancies. J Clin Oncol. 2022 02 01; 40(4):356-368.J Clin Oncol2021-12-02T00:00:002021Randomized Phase III BMT CTN Trial of Calcineurin Inhibitor-Free Chronic Graft-Versus-Host Disease Interventions in Myeloablative Hematopoietic Cell Transplantation for Hematologic Malignancies.36311784Zou J, Kongtim P, Srour SA, Greenbaum U, Schetelig J, Heidenreich F, Baldauf H, Moore B, Saengboon S, Carmazzi Y, Rondon G, Ma Q, Rezvani K, Shpall EJ, Champlin RE, Ciurea SO, Cao KFrontiers in immunologyDonor selection for KIR alloreactivity is associated with superior survival in haploidentical transplant with PTCy. Front Immunol. 2022; 13:1033871.Front Immunol2022-10-13T00:00:002022Donor selection for KIR alloreactivity is associated with superior survival in haploidentical transplant with PTCy.34112701Kondo T, Ikegawa S, Fukumi T, Sumii Y, Sugiura H, Sando Y, Nakamura M, Meguri Y, Iwamoto M, Maeda Y, Matsuoka KIImmunoHorizonsPretransplant Short-Term Exposure of Donor Graft Cells to ITK Selective Inhibitor Ameliorates Acute Graft-versus-Host Disease by Inhibiting Effector T Cell Differentiation while Sparing Regulatory T Cells. Immunohorizons. 2021 06 10; 5(6):424-437.Immunohorizons2021-06-10T00:00:002021Pretransplant Short-Term Exposure of Donor Graft Cells to ITK Selective Inhibitor Ameliorates Acute Graft-versus-Host Disease by Inhibiting Effector T Cell Differentiation while Sparing Regulatory T Cells.true1ProfessorProfessortrue1ProfessorProfessortrue1ProfessorProfessortrue1ProfessorProfessortrue1Associate ProfessorAssociate Professor